Downgrade-triggered selling has driven LLY shares down over 7% into the low $900s, while pre-market flows are only boosting the tape 0.1% toward $986.

Revenue grew over 40% to $19.3 billion in Q4 2025, driven by triple-digit sales growth of Mounjaro and Zepbound—which now account for 56% of total revenues. Lilly commands roughly 60% of the U.S. GLP-1 weight-loss market with $1.5 billion in pre-launch inventory ready to ship, and it is advancing a deep pipeline—from retatrutide and orforglipron to pediatric and dermatology candidates—while expanding manufacturing capacity globally and investing in advanced R&D infrastructure. Full-year 2026 guidance targets $80–83 billion in revenue and continued margin expansion.

Global weight-loss therapy demand outstrips supply at times, driving competition among dominant GLP-1 injectables and emerging oral pills. U.S. pricing is being reshaped by Medicare Part D coverage details, Trump’s MFN policy, and anticipated 2026 price cuts, while regulatory filings for orforglipron and retatrutide trials expand market entry timelines. Geopolitical strategies include a $7 billion China acquisition and a $3 billion investment plan amid local supply-chain navigation, as incumbents brace for generics after patent cliffs and new entrants pursue in-licensing. Competitive structure remains led by Lilly and Novo, with share shifts influenced by pill-first launches and global launch models.

Investors remain optimistic about Lilly’s dominance in the rapidly growing weight-loss and cardiometabolic market, buoyed by blockbuster GLP-1 launches, strong pipeline readouts, and forecasts of nearly $100 billion in sales by decade’s end, though caution lingers over lofty valuation multiples, potential price competition, and the upcoming FDA decision on its oral obesity candidate.